Aizen is an AI-driven biotechnology company pioneering Mirror Peptides, a novel class of biologic medicines. Mirror Peptides are synthetic, fully D-amino acid peptides that represent a vast, unexplored therapeutic chemical space that provide enhanced therapeutic stability and reduced exogenous immunogenicity for patients.

Aizen discovers these Mirror Peptides through a proprietary, AI protein design platform developed by Caltech Professor David Van Valen, MD. Backed by life science venture capital and based in the biotech hub of San Diego, CA, Aizen is advancing a diverse portfolio of therapeutics for diseases in neurological disorders, solid tumor cancers, and genetic diseases.